Administration of recombinant IL-2 augments the level of serum IgM in an IL-2 deficient patient.
A patient with ataxia telangiectasia was treated with recombinant interleukin-2 (rIL-2) and the resulting immunological effects evaluated. The patient lacked IL-2 production, and immunoglobulin synthesis was also impaired. Treatment with IL-2 selectively increased serum IgM without any significant side effects. Therapy also restored B-cell function in vitro. IgM production as well as the proliferative response to Staphylococcus aureus strain Cowan I. These results suggest that IL-2 treatment may correct both T-cell and B-cell defects.
Doi
S
S
Third Department of Internal Medicine, Osaka University Hospital, Japan.
Saiki
O
O
Hara
T
T
Sugita
T
T
Ha-Kawa
K
K
Tanaka
T
T
Hara
H
H
Negoro
S
S
Yabuuchi
H
H
Kishimoto
S
S
D000293:Adolescent; D001260:Ataxia Telangiectasia / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007075:Immunoglobulin M / Q000032:analysis*; D007376:Interleukin-2 / Q000276:immunology / Q000627:therapeutic use*; D008297:Male
D007075:Immunoglobulin M; D007376:Interleukin-2